

Lecture Abstract or Synopsis for publication

A New Treatment Option in SGLT2 inhibitor – Ertugliflozin

Seung-Hwan Lee

*Division of Endocrinology and Metabolism, Department of Internal Medicine, The Catholic University of
Korea, Korea*

hwanx2@catholic.ac.kr

Abstract

The recent ADA 2019 Guideline recommends SGLT2 inhibitors or GLP-1 receptor agonists in patients with established atherosclerotic cardiovascular diseases and those with a need for weight loss promotion. Aligned with this change, recently the Korean Diabetes Association has also changed its recommendation level of SGLT2-inhibitors. A more recent addition to the class of SGLT2 inhibitors is Ertugliflozin. Ertugliflozin is a novel highly selective and potent SGLT2-inhibitor with proven HbA1C reduction data seen in the VERTIS Trials- VERTIS-Mono, VERTIS-MET, VERTIS-SITA, VERTIS-SITA2, VERTIS FACTORIAL, VERTIS ASIA. The efficacy of Ertugliflozin has also been compared in indirect comparison studies using methods of NMA (Network Meta-Analysis) and MBMA (Model-Based Meta-Analysis). Ertugliflozin also has an indication and have been studied in combination studies with Sitagliptin, the most commonly prescribed DPP4 inhibitor in Korea and also worldwide. In this talk, recent clinical data of Ertugliflozin will be reviewed.